ChemoCentryx (ChemoCentryx) ROCE % : -34.76% (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ChemoCentryx's annualized ROCE % for the quarter that ended in Jun. 2022 was -34.76%.

ChemoCentryx ROCE % Historical Data

The historical data trend for ChemoCentryx's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx ROCE % Chart

ChemoCentryx Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

13.04

-26.69

-39.67

-17.08

-31.10

ChemoCentryx Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
ROCE %	Get a 7-Day Free Trial															-35.97	-21.45	-42.13	-41.41	-34.76

ChemoCentryx ROCE % Calculation

ChemoCentryx's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-129.06	/	( ( (518.899 - 51.558)	+	(425.652 - 63.017) )	/ 2 )
	=	-129.06	/	( (467.341	+	362.635)	/ 2 )
	=	-129.06	/	414.988
	=	-31.10 %

ChemoCentryx's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	-124.26	/	( ( (440.453 - 68.807)	+	(419.39 - 76.078) )	/ 2 )
	=	-124.26	/	( ( 371.646	+	343.312 )	/ 2 )
	=	-124.26	/	357.479
	=	-34.76 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

ChemoCentryx (NAS:CCXI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ChemoCentryx ROCE % Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ChemoCentryx (ChemoCentryx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070

Website

https://www.chemocentryx.com

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Executives

Susan M Kanaya	officer: SVP Finance, CFO & Secretary	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall	director, 10 percent owner, officer: President, CEO and Director	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau	officer: SVP, Finance & Acctg Officer	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt	officer: EVP, Chief Operating Officer	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards	director	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel	officer: CBO and Treasurer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan	officer: Principal Acctg Officer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh	officer: SVP, Research	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027